top of page
Browse by category
Search

Novo Nordisk completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Novo Nordisk has announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor...

Amycretin achieves 13% weight loss within three months with once-a-day tablet
Individuals who received a once-a-day oral weight loss drug, Amycretin developed by Novo Nordisk, lost up to 13% of their body weight...
Browse by tag






bottom of page